Aligos Therapeutics (NASDAQ:ALGS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently ...

Apex Legends remains one of the most popular first-person shooters year after year, and its esports scene continues to grow as well. The Year 5 ALGS Open is set ...

The inaugural ALGS Open is set to begin at the Ernest N. Morial Convention Center from May 1-4, 2025, marking what is expected to be the largest LAN tournament in Apex Legends history. The four-day ...

EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holdersLight Up your Portfolio with Spark:Easily identify ...

The latest price target for Aligos Therapeutics (NASDAQ:ALGS) was reported by HC Wainwright & Co. on March 31, 2025. The analyst firm set a price target for $70.00 expecting ALGS to rise to within ...

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...

Aligos Therapeutics (ALGS) announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association ...

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the ...

“We are thrilled to see LIVMARLI approved as the first and only medication available in Japan for patients living with pruritus related to ALGS and PFIC,” said Chris Peetz, chief executive ...